Drugmakers, payers and patient advocates convened at the FDA’s White Oak campus yesterday to present before a panel of regulatory leaders about competition and innovation in the pharmaceutical industry.
The meeting, which was titled “Administering the Hatch-Waxman Amendments: Ensuring a Balance Between Innovation and Access,” opened with FDA commish Scott Gottlieb, who announced that the agency would soon release two documents intended to improve the generic approval process.
Get the full story at our sister site, Drug Delivery Business News.
The post Drugmakers talk competition & innovation with FDA leaders appeared first on MassDevice.